December 09, 2020
1 min watch
Jaeger, U et al. Summary 1194. Introduced at: ASH Annual Assembly and Exposition (digital assembly); Dec. 5-8, 2020.
Locke stories holding a scientific advisory function for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and appearing as marketing consultant with grant choices for Mobile Biomedicine Group Inc.
Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Most cancers Middle, mentioned follow-up knowledge from the JULIET trial introduced on the ASH Annual Assembly and Exposition.
He talked about gauging remedy response with Myc expression
“Sufferers who had a excessive Myc expression by immunohistochemistry had worse outcomes. That is fascinating as a result of within the pivotal CAR T-cell remedy trials for diffuse giant B-cell lymphoma, we have not seen that double hit lymphoma or double expressor lymphoma has actually been a predictor for worse outcomes. Right here, they fairly merely appeared by immunohistochemistry for Myc expression,” Locke informed Healio in a video interview.